FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Chronic Myeloid Leukaemia By Ogkologos - November 26, 2024 82 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ASC4FIRST study Source RELATED ARTICLESMORE FROM AUTHOR Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients with HER2-altered Tumours, Including NSCLC EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab to Unresectable or Advanced HCC ESMO Sarcoma and Rare Cancers Congress 2025, Lugano, Switzerland, 20-22 March MOST POPULAR Shorter, More Intensive Radiation Safe after Surgery for Prostate Cancer November 18, 2021 Lack of Benefit of Adding Immune Checkpoint Inhibitors to Chemotherapy in... December 6, 2021 Immunotherapy before Surgery Appears Effective for Some with Melanoma October 12, 2022 Cancer-Free Bell Broken by Excited Patient Who Just Got Done Battling... July 17, 2019 Load more HOT NEWS EMA Recommends Extension of Indications for Blinatumomab One Family’s Mission to Stop Hair Loss from Chemotherapy: Your Stories... What to Know About Using Activated Charcoal During Cancer What to Know About Biomarker Testing for Lung Cancer: An Expert...
